Should we perform revascularisation in patients with depressed left ventricle ejection fraction?

PCR Perspectives

Summary

Divaka Perera, main author of the REVIVED study, discusses the results of this trial with Flavio Ribichini.

REVIVE was a trial of severe ischaemic cardiomyopathy in which the primary outcome was death or heart failure hospitalization.The headline result was that there was absolutely no difference with PCI, as there was no reduction or excess of death or heart failure hospitalization.

Discover the explanations put forward to explain these results in this video!

The content of this video was filmed at #EuroPCR 2023.

See more videos here!